Imaging techniques such as positron emission tomography (PET) and magnetic resonance imaging (MRI) provide valuable information about brain tumor patients. Particularly amino acid PET, advanced MRI techniques, and combinations thereof are of great interest for the non-invasive assessment of biological characteristics in patients with primary or secondary brain cancer. A methodological innovation that potentially advances research in patients with brain tumors is the increasing availability of hybrid PET/MRI systems, which enables the simultaneous acquisition of both imaging modalities. Furthermore, the advent of ultra-high field MRI scanners operating at magnetic field strengths of 7 T or more will allow further development of metabolic MR imaging at higher resolution. This review focuses on the combination of amino acid PET with MR spectroscopic imaging, perfusion- and diffusion-weighted imaging, as well as chemical exchange saturation transfer in patients with high-grade gliomas, especially glioblastomas.
Keywords: 3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine (FDOPA); O-(2-[18F]-fluoroethyl)-l-tyrosine (FET); [11C]-methyl-l-methionine (MET); brain tumors; chemical exchange saturation transfer; diffusion-weighted imaging; high-grade glioma; hybrid PET/MRI scanner; magnetic resonance spectroscopy; perfusion-weighted imaging.